University Hospital Grenoble
Grenoble, 38000, France
Location status: Recruiting
NCT Number: NCT04911738
VIRGIL is a monocentric interventional study aiming to investigate the effect of immersion in a virtual tilted room on modulation of the verticality representation (postural vertical [PV] and visual vertical [VV]), which in turn might affect body orientation (head and trunk). To this end, the investigators will conduct a within-person randomized trial including post-stroke patients and healthy participants.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Grenoble, 38000, France
Location status: Recruiting
This project proposes to test the effect of immersion in a tilted virtual reality on verticality representation in hemisphere stroke patients showing lateropulsion and in healthy participants. The idea is to use the virtual reality as a tool to recalibrate the internal reference of verticality (contralesionally biased) in stroke patients and to experimentally create a bias in verticality perception of healthy participants, then to investigate how this modulation of the internal model of verticality might affect the erect posture. The investigators hypothesize that, in stroke patients, the recalibration of the verticality perception might ameliorate their lateropulsion, whereas in healthy participants, the experimental verticality bias introduced might induce a transient experimental lateropulsion. A transmodal modulation of the verticality perception, both on PV and VV, would imply a modulation by the virtual reality not only at the level of perception but also at the internal model of verticality, advocating for a powerful effect of this technology. The analysis of a post-effect (on verticality perception) that would continue after the intervention (immersion in the virtual titled room) would be a supplementary argument advocating for its clinical use in rehabilitation of post-stroke lateropulsion. To judge the effect of the immersion in tilted virtual reality, the following measures will be considered: (a) PV perception, (b) VV perception, (c) body orientation measured by inertial captors, and (d) weight-bearing asymmetry in erect posture assessed by posturography.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
Time frame: Days 1 and 3 if assignment to plane A or days 2 and 4 if assignment to plane B of the W2
PV consists of testing the whole body orientation in sitting, perceived as vertical by participants, in complete darkness. PV will be tested by a well-validated apparatus and paradigm (Pérennou et al Brain 2008). PV orientation will be the average orientation (in degree) of the 10 trials performed for each condition.
Time frame: Days 1 and 3 if assignment to plane A or days 2 and 4 if assignment to plane B of the W2
VV consists of testing the direction of a visual line, perceived as vertical by particpants, in complete darkness. VV will be tested by a well-validated apparatus and paradigm (Pérennou et al Brain 2008 ; Piscicelli & Pérennou 2017). VV orientation will be the average orientation (in degree) of the 10 trials performed for each condition.
Time frame: Days 1 and 3 if assignment to plane A or days 2 and 4 if assignment to plane B of the W2
Persistence of PV improvement in stroke participants and persistence of PV change in healthy participants, for at least 20 minutes after the virtual reality is stopped until a maximum of 1 hour.
Time frame: Days 1 and 3 if assignment to plane A or days 2 and 4 if assignment to plane B of the W2
Persistence of VV improvement in stroke participants and persistence VV change in healthy participants, for at least 20 minutes after the virtual reality is stopped until a maximum of 1 hour.
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Comparison between active vertical trunk orientation assessed by inertial captors at baseline and active vertical trunk orientation during the virtual reality immersion.
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Comparison between active vertical pelvis orientation assessed by inertial captors at baseline and active vertical pelvis orientation during the virtual reality immersion.
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Comparison between active vertical head orientation assessed by inertial captors at baseline and active vertical head orientation during the virtual reality immersion.
Time frame: 45 minutes every Friday during the protocol (W0, W1, W2, W3).
Comparison of lateropulsion scores assessed by the SCAle for LAteropulsion (SCALA-scale, score from 0 (no lateropulsion) to 50 (severe lateropulsion with pushing); higher scores mean a worse outcome) at the end of each week (Fridays).
Time frame: 45 minutes every Friday during the protocol (W0, W1, W2, W3).
Comparison of balance scores assessed by the modified Postural Assessment Scale for Stroke patient (m-PASS, score from 0 (major postural disorders) to 36 (no postural disorder), higher scores mean a worse outcome) at the end of each week (Fridays).
Time frame: Days 1 and 3 if assignment to plane A or days 2 and 4 if assignment to plane B of the W2
Number of participants, stroke and healthy, in whom a change from baseline ≥ 2 degrees in PV orientation was observed during immersion in a virtual tilted room. The investigators hypothesize that the majority of participants (stroke and healthy) will be responders
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Weight-bearing asymmetry assessed by posturography at baseline and during virtual reality, in patients and healthy participants. Comparison of both conditions.
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Perception of the body orientation change under virtual reality assessed by a 5-point Likert scale (ad-hoc scale, score from -2 [perception of a higher lateropulsion] to + 2 [perception of a less severe lateropulsion])
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Active vertical body orientation measures and weight-bearing asymetry before virtual reality.
Time frame: Days 2 and 4 if assignment to plane A or days 1 and 3 if assignment to plane B of the W2
Active vertical body orientation measures and weight-bearing asymetry during virtual reality.
Time frame: Days 1, 2, 3 and 4 of the W2
Systematic evaluation of virtual reality sickness with a visual analogical scale (ad-hoc scale, from 0 to 10, higher scores mean a worse outcome).
Time frame: Days 1, 2, 3 and 4 of the W2
Systematic evaluation of virtual reality sickness with a structured interview.
Time frame: Days 1, 2, 3 and 4 of the W2
Active vertical body orientation measures under three verbal conditions: : i) stand comfortably; ii) stand vertical and then iii) stand well symmetrical by distributing the weight equally between the two lower limbs.
Contact information is provided by the study sponsor or research team.
University Hospital, Grenoble
Other
VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical (VIRGIL)
Acronym: VIRGIL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06570681
Brain Diseases, Cardiovascular Diseases
Aabenraa, Region Syddanmark, Denmark
View Trial DetailsNCT07185022
Brain Diseases, Cardiovascular Diseases
Fuyang, Anhui, China
View Trial DetailsNCT06954610
Arrhythmias, Cardiac, Atrial Fibrillation
Bern, Switzerland
View Trial DetailsNCT06819657
Brain Diseases, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial Details